Abstract: Disclosed are a biomarker combination for assessing the risk of adenoma and colorectal cancer, and the use thereof, in particular a metabolic marker for assessing the risk of adenoma and colorectal cancer of a subject, and the use thereof in the preparation of a diagnostic product for evaluating the risk of adenoma and colorectal cancer. The diagnostic marker has the characteristics of high sensitivity and specificity, has higher sensitivity and specificity for early colorectal cancer diagnosis, and can be used for the early discovery of colorectal cancer, so as to buy time for patients, allow treatment to be started as soon as possible, and improve the clinical treatment effect.

Abstract: Disclosed in the present invention is an application of conjugated bilirubin as a biomarker in preparation of a diagnosis device for evaluating a risk of neonatal biliary atresia. Also disclosed in the present invention are a bilirubin content measurement method, a stable quantitative detection reagent for bilirubin, and an application of the quantitative detection reagent for bilirubin in preparation of a kit for measuring a content of the bilirubin and evaluating a risk of biliary atresia of a subject, infant hepatitis syndrome, ?1 antitrypsin deficiency disease or Alagille syndrome. Also disclosed in the present invention are a kit for measuring the content of the bilirubin or evaluating the risk of neonatal biliary atresia, an application of the kit, a method for evaluating the risk of neonatal biliary atresia, and a device for predicting the risk of neonatal biliary atresia by using an expression level of the conjugated bilirubin.